ASX RELEASE.

emyria
Advanced Therapies | Compassionate Care

20 August 2026

EMYRIA UNLOCKS TREATMENT CAPACITY, TARGETS Q4 DOSING EXPANSION

Resolution of Authorised Prescriber capacity constraints, and new therapist recruits, to support additional dosing days, targeted for Q4 2026.

- **Authorised Prescriber ('AP') capacity constraints have now been resolved** across Emyria's Perth and Queensland operations with recent AP approvals removing a key bottleneck to treatment growth[1].
- **Existing dosing capacity in Perth is now driven by current Lead Therapist capacity** which is substantially utilised, with patient waitlists supporting demand for additional therapist and treatment capacity.
- **15 new therapists** will commence training this Friday with the majority recruited for Perth, addressing the next key capacity constraint to increasing treatment volumes.
- **13 of the 15 recruits (87%) meet revised TGA Lead Therapist eligibility requirements**, comprising Clinical Psychologists, Mental Health Occupational Therapists and Mental Health Nurses.
- **Additional Perth dosing availability is targeted for Q4 2026**, subject to completion of training, clinical onboarding, integration, and scheduling of new Therapists.
- **The expanded therapist workforce is expected to increase utilisation of the existing prescribing and clinical infrastructure**, providing a capital-efficient pathway to higher treatment volumes and revenue.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in innovative mental health treatments, is pleased to announce the resolution of Authorised Prescriber capacity constraints across Emyria's Perth and Queensland operations, removing a key operational bottleneck that had been an impediment to uplifting further clinical activity.

Therapist availability has therefore become the next key capacity lever.

Emyria has moved directly to address this constraint, with 15 new therapists recruited to commence training in Perth this Friday. Of the 15 recruits, 13 (87%) meet revised Therapeutic Goods Administration ("TGA") Lead Therapist eligibility requirements comprising Clinical Psychologists, Mental Health Occupational Therapists and Mental Health Nurses.

The expanded workforce is expected to enable Emyria to better utilise available prescribing capacity and existing clinical infrastructure, progressively increasing treatment volumes as therapists complete training and clinical onboarding.

Q4 DOSING EXPANSION TARGETED

The newly recruited therapists will undertake structured training, followed by clinical onboarding, and integration into Emyria's treatment model, rostering and scheduling.

Subject to the successful completion of these processes, Emyria is targeting additional Perth dosing days during Q4 2026**.**

The expansion of the therapist workforce is expected to enable the Company to increase treatment volumes and improve utilisation of existing prescribing capacity and clinical infrastructure**,** providing a capital-efficient pathway to revenue growth.

Emyria will continue to align workforce capacity with patient demand, clinical requirements, and available prescribing capacity as its clinical service operations scale.

GLOBAL PSYCHEDELIC MEDICINE MOMENTUM

Emyria's capacity expansion comes as pharmaceutical investment and clinical validation in psychedelic medicine continue to accelerate globally**.**

In July 2026, Eli Lilly announced an agreement to acquire AtaiBeckley for up to US$3.8 billion, comprising US$2.8 billion upfront and up to US$1.0 billion in milestone payments[2]. In August 2026, Definium Therapeutics reported positive Phase 3 results for DT120 in generalised anxiety disorder[3]**.**

These developments reinforce the growing convergence of pharmaceutical capital, clinical validation and commercial interest in psychedelic medicine, supporting Emyria's strategy of building scalable clinical infrastructure and treatment delivery capability in Australia.

Executive Chair, Greg Hutchinson, commented:
"The recruitment of 15 additional therapists, the majority of whom already meet the revised TGA Lead Therapist requirements, is a significant step towards unlocking additional treatment capacity and in turn support increased utilisation once therapists are trained and onboarded. Importantly, this capacity expansion comes at a time of significant momentum and investment in psychedelic medicines, globally."

References

1) Refer ASX announcement 29 July 2026, pg3, Scalable Contractor workforce
2) https://www.forbes.com/sites/robertglatter/2026/07/20/big-pharma-and-psychedelic-medicine-eli-lillys-38-billion-bet/
3) https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder

For further information, investment opportunities, or more about Emyria's approach to mental health treatment, please contact:

Greg Hutchinson
Executive Chair
1300 436 363 | investors@emyria.com

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:



Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.